Jubilant Ingrevia Ltd

- The company plans to complete the remaining Rs. 600 crore CAPEX out of the Rs. 2,000 crore plan by FY25 without expecting an increase in debt, assuming market recovery begins in Q1 FY25. - If the market recovery is delayed, the company may postpone additional CAPEX beyond the original plan by a few quarters to maintain current debt levels. - There is no indication of immediate new equity fundraising. - The company is maintaining financial discipline and plans to balance CAPEX with profitability, focusing on operating within existing debt limits. - Any new CAPEX items beyond the planned Rs. 2,000 crore will be considered cautiously and likely deferred if markets do not improve. - Net debt as of December 31, 2023 was Rs. 636 crore with a Net Debt to EBITDA ratio of 1.36x; efforts to reduce debt further through lean initiatives are ongoing.

- Remaining CAPEX of approx. Rs. 600 crore from the Rs. 2,000 crore plan will be deployed in FY25, mainly in Specialty Chemicals, Nutrition & Health segments, including agro chemical plants, food and cosmetic-grade niacinamide, value-added diketene derivatives, and new boiler and power plant at Bharuch. - Additional CAPEX plans are under internal review based on emerging opportunities and customer traction; any new CAPEX beyond the original Rs. 2,000 crore plan may be delayed by quarters if market recovery is slow. - Recent/completed CAPEX includes commissioning of an agro intermediates plant in Q3 FY24, with two more plants planned for Q4 FY24 (diketene derivative expansion and agro active cum intermediate). - A niacinamide plant (cosmetic and food-grade) is expected to start around June FY25. - The company is exploring strategic partnerships and new product segments such as semiconductor chemicals through its CDMO business. - Capital allocation aims at maintaining financial discipline without significant increase in debt assuming market recovery in Q1 FY25.

- Agrochemical segment expected to recover starting H1 FY25 with volume uptick by end Q4 FY24; potential 20-25% YoY growth anticipated. - Specialty Chemicals showing growth in non-agro segments like Diketene derivatives, microbial, CDMO, and Pharma, with capacity utilization targeted at 70%+ within 18 months. - Positive momentum in CDMO business, considered the fastest-growing segment in Specialty Chemicals, with prospects in pharma, agro, and semiconductor chemicals. - Capacity expansions underway: new agro intermediates and Diketene plants commissioning in Q4 FY24; Niacinamide facility by Q2 FY25. - Market share expected to increase due to competitor exit (Vertellus), potentially capturing 70-80% of displaced volumes in pyridine derivatives. - Overall company growth driven by successful CAPEX execution (Rs. 2,000 crore plan on track) and strategic partnerships. - Lean initiatives and cost controls aimed at improving profitability alongside volume growth.

- Agrochemical segment, which contributes about 30% of the business, has declined but is expected to recover with volume growth anticipated from H1 FY25 onwards, potentially leading to overall company growth. - Specialty Chemicals, especially CDMO business, is the fastest-growing segment expected to drive future growth, with new opportunities in pharma, agrochemicals, and semiconductor chemicals. - Capacity utilization for new plants is expected to reach 70%+ within 18 months as demand recovers. - EBITDA margins are currently under pressure due to lower volumes and pricing, but an uptick in margins is expected with market recovery. - Management expects fiscal FY25 to be a growth year, with possibly 20%-25% growth year-on-year in estimates, depending on market conditions. - The company aims to maintain financial discipline while deploying Rs. 600 crore planned CAPEX for FY25, without significantly increasing debt. - New digital and energy efficiency initiatives are expected to improve yield, efficiency, and cost structures in the coming years.

- The company is seeing inquiries from customers who were previously served by the largest competitor, Vertellus, which exited the business. - Actual order bookings from these customers are currently small but expected to increase as market demand recovers. - For pyridine and picoline products, volumes are already booked for the next few quarters, indicating a good sign of demand recovery. - There is good traction and advanced discussions with 4-5 customers for semiconductor chemicals in their CDMO business. - Utilization in new capacities, such as the recently commissioned agro intermediates MPP plants, is expected to ramp up to 70%-80% within 18 months given anticipated market recovery. - Overall, the expectation is that volume uptick and orders will accelerate from Q1 FY25 onwards as agrochemical markets pick up and inventories dry down globally.